Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatocyte nuclear factor 1 alpha (HNF1A) is a DNA-binding transcription factor from the HNF1 homeobox protein family, encoded by the HNF1A gene on chromosome 12q24.2. It contains a dimerization domain, an atypical POU-homeodomain for DNA binding, and a C-terminal transactivation domain. HNF1A regulates the expression of liver-specific and pancreatic genes involved in glucose transport, metabolism, and insulin secretion, playing a central role in glucose and lipid homeostasis as well as cell differentiation in liver, kidney, and pancreas. Mutations in HNF1A cause monogenic diabetes (MODY3) and are implicated in hepatic tumors and increased cardiovascular risk. Although no approved therapeutics directly target HNF1A, knowledge of its mutation status guides clinical management, especially in diabetes subtypes where sulfonylurea treatment is effective.
In MODY3, sulfonylureas increase insulin release from pancreatic β-cells with defective HNF1A-mediated transcription; therapy leverages the remaining β-cell function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatocyte nuclear factor 1 alpha (HNF1A).